Data from Genkyotex’s GKT137831 Phase I studies to be presented at Kidney Week 2012

Genkyotex, the leading developer of NOX inhibitors to treat oxygen-radical mediated diseases, announced today that data from single and multiple dose Phase I studies with the NOX 1 and 4 inhibitor, GKT137831, will be presented at Kidney Week 2012 (San Diego, October 30 - November 4).

The Phase I data will be presented in the Pharmacokinetics (PK)/ Pharmacodynamics (PD) session:

Friday, November 2, 2012, 10.00 AM -12.00 PM

PosterBoard# FR-PO831; Abstract# 2279

Safety and Pharmacokinetics of Single and Multiple Doses of a First in Class Dual NADPH Oxidase 1 and 4 Inhibitor Administered Orally in Health Subjects

Preliminary Phase I results released earlier this year showed that GKT137831 is safe and well tolerated following oral administration of single doses in 36 healthy subjects. Genkyotex plans to advance GKT137831 into a Phase II trial in patients with diabetic nephropathy.